Verapamil vs Steroid to Prevent Keloid Recurrence
- Registration Number
- NCT01720056
- Lead Sponsor
- The University of Western Australia
- Brief Summary
Keloid scarring is a severe cosmetic and painful disease of the skin. The gold standard treatment is yet to be clarified. This randomized clinical pilot study will compare the effects of two local treatments for preventing keloid recurrence after surgical removal; steroid and verapamil.
Study hypothesis: Intralesional therapy with the calcium antagonist verapamil has equal treatment efficacy as steroid injection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- Patient undergoing surgical removal of keloid
- Patient 18 years old or greater
- Length of excisional scar after surgical removal of keloid between 2 and 10 cm
Exclusion Criteria
- Keloid in face or hands
- Pregnancy or lactation
- Dementia
- Any heart or pulmonary condition
- Systemic treatment with beta-blockers, ACE-inhibitors or calcium antagonists
- Systemic corticosteroidal therapy
- Intralesional steroid treatment within 2 months of surgery to remove keloid
- Flap surgery
- Lesions to face, hands and other cosmetically sensitive areas
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Kenalog 10 Kenalog 10 Kenalog 10 mg/mL injection sc intralesionally Verapamil Verapamil Verapamil 2.5 mg/mL injection sc intralesionally
- Primary Outcome Measures
Name Time Method Keloid recurrence 1 year
- Secondary Outcome Measures
Name Time Method Vancouver Scar Scale Score 1 year
Trial Locations
- Locations (1)
Royal Perth Hospital
🇦🇺Perth, Western Australia, Australia